GlassScriptPhysician profile
Lydia C Tanner
NPI 1790799740
$10,287.26
in general payments reported to CMS, 2019-2025
44 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,711 · 2020: $1,601 · 2021: $1,530 · 2022: $1,312 · 2023: $1,443 · 2024: $1,396 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,039 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,039.30 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,930.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,800.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $890.44 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $645.63 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $572.13 | 2019-2023 | Seglentis, Livalo |
| Amgen INC. | $506.95 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $395.56 | 2019-2023 | Belsomra, Steglatro, Verquvo |
| Abbvie INC. | $391.98 | 2020-2025 | |
| Astellas Pharma US INC | $336.94 | 2019-2024 | Myrbetriq, Veozah |
| Janssen Pharmaceuticals, INC | $298.24 | 2019-2024 | Xarelto |
| Pfizer INC. | $285.11 | 2019-2025 | |
| Lilly USA, LLC | $280.27 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $277.25 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $252.50 | 2019-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $151.08 | 2022-2025 | Quviviq, Quviviq |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $99.36 | 2019-2022 | |
| Allergan, INC. | $95.68 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $92.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $78.09 | 2019-2023 | |
| Ibsa Pharma INC. | $75.18 | 2021-2024 | Tirosint, Licart, Tirosint |
| Abbott Laboratories | $74.22 | 2023-2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $68.28 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $67.70 | 2021-2023 | Gvoke Hypopen |
| Philips North America LLC | $66.33 | 2024-2025 | (5091) Amb Mon & Diag Und, (Ck4) Mcot, Extended Holter |
| Dexcom, INC. | $58.62 | 2021-2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $54.12 | 2021-2025 | Rexulti, Nuedexta |
| Daiichi Sankyo INC. | $53.25 | 2020-2022 | |
| Eisai INC. | $44.76 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $35.60 | 2024-2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.97 | 2024-2025 | Xifaxan |
| Medtronic, INC. | $30.04 | 2022-2023 | Minimed 780g |
| Sumitomo Pharma America, INC. | $24.64 | 2023 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $23.37 | 2020 | |
| Quidel Corporation | $23.06 | 2023 | |
| Ironwood Pharmaceuticals, INC | $21.24 | 2020 | |
| Horizon Therapeutics Plc | $19.88 | 2023 | Krystexxa |
| Exact Sciences Corporation | $18.06 | 2025 | The Cologuard Plus Collection Kit |
| Antares Pharma, INC. | $18.02 | 2025 | Xyosted |
| Axsome Therapeutics, INC. | $17.95 | 2024 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $17.87 | 2022 | |
| Valeritas, INC. | $16.36 | 2019 | |
| Verona Pharma, INC. | $15.18 | 2025 | Ohtuvayre |
| Bausch Health US, LLC | $15.10 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.